During the past decade, Wits RHI Shandukani Research Centre CRS conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 12 clinical trials were completed, i.e. on average, 80% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 8 clinical trials were completed. i.e. 80% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Wits RHI Shandukani Research Centre CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 17 trials, followed by "Janssen Vaccines & Prevention B.V." with 3 trials sponsored, "PATH" with 2 trials sponsored, "Pfizer" with 1 trials sponsored and "University of Oxford" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Wits RHI Shandukani Research Centre CRS" #1 collaborator was "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 8 trials as a collaborator, "Bill and Melinda Gates Foundation" with 2 trials as a collaborator, "Gilead Sciences" with 2 trials as a collaborator, "International Maternal Pediatric Adolescent AIDS Clinical Trials Group" with 2 trials as a collaborator and "National Institute of Mental Health (NIMH)" with 2 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Wits RHI Shandukani Research Centre CRS" are "HIV Infections" (14 trials), "HIV" (2 trials), "Tuberculosis" (2 trials), "COVID-19 Prevention" (1 trials) and "Coronavirus" (1 trials). Many other conditions were trialed in "Wits RHI Shandukani Research Centre CRS" in a lesser frequency.

Most popular intervention types in "Wits RHI Shandukani Research Centre CRS" are "Drug" (17 trials), "Biological" (7 trials), "Other" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ad26.COV2.S" (3 trials), "Placebo" (3 trials), "Truvada Tablet" (2 trials), "ATV" (1 trials) and "Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC) Dispersible Tablets" (1 trials). Other intervention names were less common.

The vast majority of trials in "Wits RHI Shandukani Research Centre CRS" are 19 trials for "All" genders and 5 trials for "Female" genders.

Currently, there are NaN active trials in "Wits RHI Shandukani Research Centre CRS". undefined are not yet recruiting, 2 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Wits RHI Shandukani Research Centre CRS, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Wits RHI Shandukani Research Centre CRS, 11 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".